Merck Emend
Presence of particulate matter: potential presence of metal particulates in the product.
676 recalls · Class II, newest first
Presence of particulate matter: potential presence of metal particulates in the product.
Failed Impurity/Degradation specifications: OOS results obtained at the 18-month timepoint
cGMP Deviations
cGMP Deviations
Presence of Foreign Tablets/Capsules
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
Incorrect Product Formulation
Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
CGMP Deviations: the presence of a nitrosamine impurity, N-nitroso-cinacalcet, above the acceptable daily intake (ADI) limits.
Failed impurities/degradation specifications: out of specification results for Ganirelix acetate acrylic acid adduct impurity.
Microbial contamination of a non-sterile product - microorganism found to be pseudomonas lactis
Defective container - seal not adhering to bottles
Defective container: cracked/broken cartridges
Defective container: cracked/broken cartridges
Defective container: cracked/broken cartridges
Defective container: cracked/broken cartridges
Defective container: cracked/broken cartridges
Defective container: cracked/broken cartridges
Defective container: cracked/broken cartridges
cGMP deviations
cGMP deviations
cGMP deviations